Abstract
409 patients were randomly allocated to receive either formestane (f) 250mg i.m. fortnightly or tamoxifen (t) 30mg orally o.d. in a multinational, prospective, open trial. The efficacy and tolerability results were previously reported in the Annals of Oncology 1994, Vol 5 (Supp 7) 519–524. Further analysis has been performed to confirm the survival data now that it has matured, including 218 additional visits from 67 patients. There was no difference between treatments in survival, (1062 (f) vs 1079 (t) days). During the follow-up period of this trial, 84 patients, (48 (f), 36 (t)) achieved further response to other anticancer therapy, indicating that these patients remained responsive regardless of which endocrine therapy they received for first -line.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
